Clinical trial
Sublingual Methadone for the Management of Cancer Breakthrough Pain
NCT00125294 · AHS Cancer Control Alberta, Other · Completed
Key facts
| NCT number | NCT00125294 |
|---|---|
| Title | Sublingual Methadone for the Management of Cancer Breakthrough Pain |
| Official title | Evaluation of a Dose Titration Protocol for Sublingual Methadone Hydrochloride for the Management of Cancer-related Breakthrough Pain |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Collaborators | Calgary Health Region |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Pain |
| Intervention type | Drug |
| Interventions | Methadone |
| Enrollment | 10 |
| Start date | Sep 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Aug 1, 2005 |
| Last update posted | Sep 25, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: